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Abstract
Background: Over half of men who receive treatment for prostate suffer from a range of sexual problems that
affect negatively their sexual health, sexual intimacy with their partners and their quality of life. In clinical practice,
however, care for the sexual side effects of treatment is often suboptimal or unavailable. The goal of the current
study is to test a web-based intervention to support the recovery of sexual intimacy of prostate cancer survivors
and their partners after treatment.
Methods: The study team developed an interactive, web-based intervention, tailored to type of treatment received,
relationship status (partnered/non-partnered) and sexual orientation. It consists of 10 modules, six follow the
trajectory of the illness and four are theme based. They address sexual side effects, rehabilitation, psychological
impacts and coaching for self-efficacy.
Each includes a video to engage participants, psychoeducation and activities completed by participants on the web.
Tailored strategies for identified concerns are sent by email after each module. Six of these modules will be tested in a
randomized controlled trial and compared to usual care. Men with localized prostate cancer with partners will be
recruited from five academic medical centers. These couples (N = 140) will be assessed prior to treatment, then 3 months
and 6 months after treatment. The primary outcome will be the survivors’ and partners’ Global Satisfaction with Sex Life,
assessed by a Patient Reported Outcome Measure Information Systems (PROMIS) measure. Secondary outcomes will
include interest in sex, sexual activity, use of sexual aids, dyadic coping, knowledge about sexual recovery, grief about the
loss of sexual function, and quality of life. The impact of the intervention on the couple will be assessed using the
Actor-Partner Interaction Model, a mixed-effects linear regression model able to estimate both the association of partner
characteristics with partner and patient outcomes and the association of patient characteristics with both outcomes.
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Discussion: The web-based tool represents a novel approach to addressing the sexual health needs of prostate cancer
survivors and their partners that—if found efficacious—will improve access to much needed specialty care in prostate
cancer survivorship.
Trial registration: Clinicaltrials.gov registration # NCT02702453, registered on March 3, 2016.
Keywords: Prostate cancer sexual recovery cancer survivorship intervention
Background
Research on older adults has found that couples who re-
tain their sexual relationships have a better quality of life
(QOL) [1–4] whereas disruption of these relationships
can lead to distancing, loneliness, and depression [1, 5].
Being in a relationship is associated with improved can-
cer survival and sexual relationships are an important
source of resilience for patients with cancer [2]. Among
men with prostate cancer, treatment-related erectile dys-
function (ED) [3] has a detrimental impact on survivors’
lives, on their partners and on their relationships [4, 6].
Although it is important for men and their partners to
retain sexual viability after prostate cancer treatment,
there are currently no guidelines for helping men and
couples manage post-treatment sexual health. As a re-
sult, couples seldom receive the help they need in this
aspect of prostate cancer survivorship.
While sexuality has biopsychosocial components,
current management of the sexual side effects of pros-
tate cancer treatment focuses only on treating
treatment-related physiologic dysfunction – ED - with
various erectile aids [7]. Studies indicate that many men
who stand to benefit from these treatments do not
utilize them if the psychosocial aspects of sexuality are
not addressed [8–10]. The psychosocial aspects of sexu-
ality include feelings about one’s sexual function, ability
to feel pleasure, confidence as a lover and skill with
which to navigate a sexual relationship [11]. Some psy-
chosocial factors can become potentially influential bar-
riers to sexual recovery after prostate cancer treatment,
such as unrealistic expectations of functional recovery,
lack of knowledge about sexual rehabilitation, unre-
solved grief about sexual losses, couple conflict, and ex-
tensive family responsibilities [12, 13]. Studies have
shown that this biopsychosocial approach to post-
prostate cancer sexual recovery can be effective [14].
Patients and providers frequently lack an understand-
ing of the complexity of sexuality, and are uncomfort-
able with the subject [15–17]. Providers are generally
unprepared for these conversations and are unaware of
sexual health resources. At times, they are uncertain
about some available therapies. For example, although
there is increasing evidence supporting the safety of tes-
tosterone replacement therapy (TRT) in some prostate
cancer survivors, many providers are unsure about when
to initiate therapy, or how to appropriately monitor pa-
tients on TRT [18]. Access to sexual health expertise
that focuses not only on physiologic ED treatments but
also on the psychosocial aspects of sexuality [11] is fre-
quently unavailable. Many insurances do not cover med-
ications and devices as well as sexual dysfunction
diagnoses despite the fact that those diagnoses are a part
of the mental health insurance codes and their coverage
could facilitate access to sexual health treatment [19]. As
a result, the healthcare system does not adequately sup-
port patients and partners in their pursuit of sexual
health after prostate cancer treatment.
Recognizing the multiple, overlapping barriers to sex-
ual recovery after prostate cancer treatment, researchers
are designing interventions specifically aimed at improv-
ing sexual outcomes. Although small in number, inter-
ventions that have attempted to address the psychosocial
aspects of sexuality have shown a number of positive
outcomes such as stress reduction, temporary improve-
ment in sexual function, increased knowledge about re-
habilitation, more realistic expectations about the
recovery of sexual function, use of pro-erectile aids and
higher levels of relationship satisfaction [14, 20–27].
Studies have also shown that physical exercise can have
a positive effect on the recovery of erectile function, and
on the maintenance of a masculine self-image [28, 29].
Evidence continues to be mixed and the search for
meaningful measurable outcomes is still in process [30].
Beyond the development of suitable interventions for
couples, other gaps exist. One such gap is the lack of
dissemination of tested interventions in prostate cancer
beyond the research setting. Another is the lack of re-
search that incorporates important sociodemographic
factors, cultural differences, and sexual orientation that
may impact sexual recovery after prostate cancer. There
are very few studies about African American men with
prostate cancer [31]. There is a paucity of research on
the attitudes of men from other racial/ethnic groups that
may be used to inform the tailoring of interventions
[32]. Similarly, research on gay men with prostate cancer
has been largely missing in the literature [33], thus leav-
ing as many as 11,000 gay men with prostate cancer
each year without attention to their specific sexual
health care needs [34]. There is no research on the effect
of prostate cancer-related sexual dysfunction on men
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who are not partnered. Finally, few studies focus on men
treated with androgen deprivation therapy (ADT) as
health care providers may mistakenly assume that sexual
recovery is not an important consideration for these pa-
tients [35, 36]. Preferences based on cultural back-
ground, sexual orientation, and an understanding of
men on ADT need to be incorporated into sexual health
interventions so that the interventions can be tailored to
these survivors’ needs.
Web-based interventions may be an important
mode of delivery of sexual recovery interventions for
prostate cancer survivors. They can address multiple
barriers to dissemination and allow for a tailored ap-
proach. Although prostate cancer patients and part-
ners are primarily an older cohort, they are
frequently internet-literate and have shown a high
interest in and ability to collaborate with providers
online [37–39]. Web-based interventions may be es-
pecially useful for patients who live far away from
the clinic, for those for whom clinic visits may pose
an economic burden (e.g., those whose travel costs
are high or who have difficulty taking time away
from work), and for those survivors who find topics
such as sexual health difficult to approach in a face-
to-face visit. A web-based approach has also been
shown to be valuable to cancer patients with fewer
social support resources [40]. In prostate cancer,
couples, not just individual men with prostate cancer
have also benefited from a web-based intervention
aimed at reducing distress [41]. In the setting of sex-
ual recovery, an intimacy enhancement and psychoe-
ducational sexual health intervention was shown to
have been equally acceptable to patients in web-
based and face-to-face formats [20].
In this manuscript, we describe a novel intervention
that delivers web-based content for sexual recovery for
men with prostate cancer. The intervention is tailored
based on partnership status, treatment type and sexual
orientation, with sensitivity to cultural differences. It is
designed to allow men and their partners to participate
in it together. We present the theoretical model which
underlies the intervention approach. The study design,
assessments, and analytic approach are also presented.
The national collaborative
The Movember Foundation has collaborated with na-
tional non-profit organizations, such as the Livestrong
Foundation (United States) and the Prostate Cancer
Foundation (Australia, the United Kingdom, the United
States and Canada) to offer funding to selected institu-
tions with a clinical and research track record in pros-
tate cancer survivorship. A Request for Proposals in the
United States was issued in the fall of 2013, and 15 insti-
tutions were selected: Johns Hopkins University, Emory
University, Harvard University, Memorial Sloan Ketter-
ing Cancer Center, Moffitt Cancer Center, University of
California San Francisco, Los Angeles and Davis, Univer-
sity of Michigan, University of Washington, Oregon
Health Sciences University, University of Colorado-
Denver, Wayne State University, Duke University and
University of North Carolina. In March 2014, represen-
tatives from the 15 institutions met to define priorities
for interventions, and agreed to participate in building
those interventions in which they had the most experi-
ence. Sexual Recovery was one of the priorities selected
for intervention building.
The Sexual Recovery Intervention was developed by a
team (i.e., the Full Team) of sexual health experts, urolo-
gists, psychologists, health services researchers, epidemiol-
ogists, primary care physicians, radiation oncologists,
medical oncologists, nurses (one of these professionals is a
survivor and another one is a partner), and survivor and
partner advocates from 11 institutions (Emory University,
University of Colorado-Denver, University of California-
Los Angeles, Johns Hopkins University, Fred Hutchinson
Cancer Research Center, University of Michigan, Duke
University, Memorial Sloan Kettering and Harvard Uni-
versity, University of North Carolina, University of
California-San Francisco). A Design Team was established
to write a proposal for intervention development and test-
ing. It included a sexual health expert, a primary care
physician, a urologist, and an internal medicine physician
with expertise in information technology. The Full Team
participated in monthly teleconferences and also provided
regular electronic editorial contributions. After peer re-
view by the Scientific Committee of the Movember Foun-
dation, the protocol was amended and re-submitted for
funding. Funding was assigned in March 2015.
The intervention was developed at the University of
Michigan, given the institution’s expertise in sexual
health and technology. However, the Design Team
and the Full Team provided critical feedback during
the development phase. The intervention is currently
being tested in a multi-center randomized controlled
trial (RCT) involving five institutions in the United
States (Emory University, University of California-Los
Angeles, Memorial Sloan Kettering Cancer Center,
Johns Hopkins University and the University of Mich-
igan). Plans are in progress to adapt the intervention
in the United Kingdom.
The intervention, once tested, will be integrated into a
support structure for prostate cancer survivors, partners,
and families, which will be available on the Movember
Foundation website. The prioritized US interventions have
a collective over-arching identity as True NTH (pro-
nounced ‘True North’). Its goal is “to improve the physical
and mental well-being of men living with prostate cancer,
together with their partners, caregivers and families.”
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A theoretical model of sexual recovery after prostate
cancer treatment
The proposed web-based sexual recovery intervention is
underpinned by a theoretical model that benefits from
existing research. It was tested in a mixed methods study
to ensure content validity by the principal investigator
and colleagues [42]. It is based on the biopsychosocial
understanding of sexuality [11, 43]. Recognizing that ED
and subsequent changed sexuality represent loss for both
the man and the partner [44, 45], the model incorpo-
rates concepts from the grief literature to suggest that
sexual recovery includes, at least in part, a grief process
[46, 47].
Study overview
The study’s first step was to develop the intervention
and conduct formative testing with 3 focus groups which
included 4 heterosexual couples, 8 survivors and 8 part-
ners, respectively. Two non-heterosexual couples were
interviewed separately as we were unable to recruit for a
full focus group. Usability testing was conducted with 5
couples and 5 individual survivors who commented,
while working through the intervention, on the ease of
use, relevance, content and graphics. The majority of the
participants endorsed the web-based format and sug-
gested that the intervention include preparation for the
sexual side-effects, rehabilitation, preparation for the
emotional impact of erectile dysfunction and diminished
libido on couples, education for partners about the im-
portance of erections to men, sensitivity to gay sex and
education of providers regarding sexuality of men who
have sex with men [48].
Figure 1 illustrates the study process for the interven-
tion group, starting prior to diagnosis with preparation
for the sexual side-effects, their impacts and rehabilita-
tion, and continuing with support for sexual recovery
through 6 months after treatment (also the study com-
pletion). The figure also illustrates where the interven-
tion modules of the TrueNTH Sexual Recovery
Intervention will aim to affect the process of couples’ re-
covery. One of the modules (M10) coaches patients and
partners to engage comfortably in discussions with
healthcare providers about sexual problems and solu-
tions. Finally, the figure includes measurement of the ef-
fect of the intervention on outcomes proposed in this
protocol.
This study aims to evaluate the effect of 6 modules of
the intervention in an RCT on patients’ and partners’
satisfaction with their sex life, compared to usual care at
6 month follow up. It is hypothesized that patients and
partners who participate in the online intervention will
report more satisfaction with their sex life than the
Fig. 1 Tailored web-based intervention to support couples’ sexual recovery after treatment for localized prostate cancer (RCT of 6 modules in a
pre-treatm6nt to 6-month post-treatment time-frame)
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control group. The intervention group is also expected to
report greater knowledge about sexual recovery, less in-
tense grief about sexual losses, more interest in sex, greater
use of sexual aids, better dyadic coping, and a higher quality
of life than the control group after treatment.
Methods
Study setting
Recruitment will take place in urology and radiation on-
cology clinics at participating sites in the True NTH con-
sortium: University of Michigan, Emory University, Johns
Hopkins University, University of California –Los Angeles
and Memorial Sloan Kettering Cancer Center. Sites were
selected based on (1) patient volume which will impact
feasibility and recruitment costs, (2) diversity of the pa-
tient population, and (3) current standard of care regard-
ing sexual health. Each site will have a site PI and a study
coordinator. The website’s survey and intervention couple
engagement logistics data will be centrally managed at the
University of Michigan which will also serve as the coord-
inating site for clinical data and a provider of technical
support for all participating sites. Potential participants
will be identified by a member of the study team at partici-
pating sites through screening clinic and surgical sched-
ules as well through referral by the treating physician. The
goal for each site will be to recruit a minimum of 15 cou-
ples and a maximum of 50 couples.
Participant selection
Inclusion criteria
Patients diagnosed with localized prostate cancer will be
eligible if they are planning to receive definitive treat-
ment within 3–6 weeks after diagnosis with either radi-
ation or prostatectomy without ADT. Participants must
be in a 6 month or longer relationship with a spouse/
partner who is willing to sign an informed consent. In-
formed consent must be signed at least 2 weeks prior to
the start of treatment so that the participants will have
time to complete baseline surveys and access the first
module of the intervention. Additionally, participants
must be able to speak or read English without cognitive
deficit, not be in acute psychiatric crisis, have reliable
internet access with separate addresses for the patient
and partner, and be 18 years of age or older.
Randomization
The patient/partner dyad will be randomized to either
the intervention arm or the usual care arm after comple-
tion of the informed consents, and prior to initiation of
treatment. Randomization will be performed using a
computer-generated randomized block design to
minimize the potential for sample size differences be-
tween the two arms. The randomized block design will
be stratified by enrollment site to facilitate ease of
administration of the trial (Fig. 2). Participants random-
ized to usual care will be routed to the American Cancer
Society’s web page that provides information about the
sexual side-effects of cancer and sexual rehabilitation,
which can be considered a part of usual care. Partici-
pants will be blinded as to the arm that they are entering
by language at recruitment which will indicate that we
are comparing two supportive interventions for sexual
recovery after prostate cancer treatment. Participants
will be unblinded by letter after they complete their 6-
month survey.
Intervention
The full intervention will consist of 10 web-based mod-
ules, 6 of which are consistent with the trajectory of
prostate cancer and its treatment (Table 1). Four mod-
ules will be thematically linked to the experience of sex-
ual recovery after prostate cancer treatment.
The approach to the intervention is mindful of the a)
biopsychosocial nature of sexuality; b) need to include
information for gay men, c) representation of diverse
cultural and ethnic groups, d) recognition that recovery
does NOT mean returning to baseline, and d) the need
to involve the partner at each stage of the sexual recov-
ery process. The modules are tailored so that the con-
tent is relevant and appropriate according to (1)
partnership, (2) prostate cancer treatment type and (3)
sexual orientation. The language comprehension of the
intervention reflects users with a 6th grade education.
Although all modules were developed with the requisite
tailoring during this project, only the 6 (1,2,3,4,5,10)
modules, addressed to couples, will be tested initially in
the RCT.
Each intervention module has the following sections:
1) video introduction featuring an individual or a couple
who have gone through the prostate cancer experience
or a relevant expert, such as a sex therapist, 2) educational
content, 3) an activity for couples to engage in online, and
4) an opportunity to identify patient and partner concerns.
Each intervention module lasts approximately 45 min or
less. After each module, participants will receive, via email,
tailored strategies, based on concerns they raised during
the immediately preceding module’s activity.
Procedure and adherence to treatment
Participants who pass through the screening process will
be recruited in clinics or by telephone, depending on
their availability. They will be consented during clinic
appointments or by mail. Each couple will be given an
envelope with their study identification number (ID) and
login information with which to enroll into the True NTH
website. The login password is coded to randomize the
participating couple into the intervention or control arm
of the study. After logging in, participants will provide
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Table 1 TrueNTH Sexual Recovery Intervention Content
Module Theme Goal Content
1 Pre-treatment
education
Preparation for the sexual side-effects of prostate cancer
treatment, rehabilitation, emotional response and work-
ing on recovery as a team.
Video: couple modeling acceptance of working together
on sexual recovery.
Education: etiology and nature of treatment-related sex-
ual dysfunction, its effect on relationships, goal and type
of rehabilitation, individual and couple emotional work
that supports recovery.
Activity: sharing concerns and goals for recovery.
Request for tailored strategies: specific concerns will
trigger a tailored response delivered to patient and/or
partner by email.
2 Preparation for the
resumption of sexual
activity
Understanding of sexual rehabilitation as it relates to
erectile dysfunction, female post-menopausal challenges;
normalizing of feelings of grief about sexual losses;
maintenance of feeling connected in the face of the
sexual challenges ahead.
Video: patient discussing changes after prostate cancer
treatment and engagement in rehabilitation
Education: description of penile rehabilitation methods,
maintenance of vaginal health and taking pressure off
the sexual relationship during the early phase of
rehabilitation.
Activity: treatment-related sexual changes and post-
menopausal changes, determination of use of sexual aids
for rehabilitation by both man and partner, introduction
of rehabilitation diary, staying connected.
Request for tailored strategies: specific concerns will
trigger a tailored response delivered to patient and/or
partner by email.
3 Beginning to recover
sexual intimacy as a
couple
Recognition that sexual changes will require adaptation
by the man and the partner, likely use of sexual aids
and a need to adopt a flexible approach to sexual
interactions.
Video: A sex therapist encourages the work on sexual
recovery, movement towards a ‘new sexual normal.’
Education: Coping with sexual changes, role of grief,
management of expectations, understanding the role of
the partner, flexible approach to sexual intimacy,
potential barriers, review of sexual aids for men and
partners, sensate focus exercises.
Activity: Draw body maps to use for sensate focus
exercises. Staying connected.
Request for tailored strategies: Specific concerns will
trigger a tailored response delivered to patient and/or
partner by email.
4 Integrating sex into
life’s routine
Acceptance of “new sexual normal.” Video: Couple talking about engaging in regular,
intentional sexual activity.
Education: Importance of communication, finding time
to have sexual activity, review of choices of sexual aids,
role of non-penetrative sex and affection, mutuality in
the sexual relationship.
Activity: Develop a plan for regular sexual activity,
including sexual aids and how each partner will
contribute. Identify barriers to regular sexual activity and
how they can be overcome. Staying connected.
Request for tailored strategies: Specific concerns will
trigger a tailored response delivered to patient and/or
partner by email.
5 Effective sexuality
after prostate cancer
Review the work on sexual recovery with a sense of
accomplishment
Video: Couple discusses where they are 6 months after
treatment.
Education: Review of sexual changes, rehabilitation, use
of sexual aids, expanded sexual repertoire, grief work,
communication, participation in the study.
Activity: Worksheet to identify sexual activities practiced,
including frequency, aids used, the degree to which
emotional acceptance was reached, and what goals
were reached. Staying connected.
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basic demographic information. Patients will be asked
to identify the gender of their partner and type of
treatment they will undergo. Once this information is
entered, the couple will be sent to surveys tailored to
their sexual orientation and treatment type. They will
then be asked to fill out baseline surveys. The partici-
pants who are randomized into to the intervention
arm will access content tailored to their treatment
and sexual orientation. Participants who do not fill
out their baseline surveys will receive up to 3 phone
calls from the study coordinator at participating sites.
Those who do not fill out baseline surveys will not
be able to continue in the study. Participants who do
not log into a given module will receive up to 3 email
reminders which are programmed into the intervention.
Participants will be allowed to move forward in the inter-
vention even if they do not log into the 3-month surveys
to enable tracking their interest in the web-based support.
Fig. 2 Study progression
Table 1 TrueNTH Sexual Recovery Intervention Content (Continued)
Module Theme Goal Content
Request for tailored strategies: Specific concerns will
trigger a tailored response delivered to patient and/or
partner by email.
10 How to speak to
medical providers
about sexual
problems
Empower men and partners to feel comfortable
addressing sexual concerns
Video: Couple talking about how difficult it can be to
discuss sexual problems with their provider, and how to
overcome barriers.
Education: Emphasize the importance of engaging
providers about sexual concerns, discuss strategies for
preparing to do it, discuss roles that the man and
partner can take, encourage rehearsal.
Activity: Review of worries, priority list of questions
important to patient and partner, role-play.
Request for tailored strategies: Specific concerns will
trigger a tailored response delivered to patient and/or
partner by email.
Additional Modules that will be part of the website, but not part of the Randomized Control Trial
Module 6: Maintaining a sexual relationship for the long term
Module 7: One month after biochemical relapse
Module 8: Sexuality during advanced stages of prostate cancer
Module 9: Overcoming barriers to sexual recovery
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Participants in the intervention arm will receive up to
3 email reminders when their successive modules be-
come available. They will be able to continue in the
intervention even if they do not access the modules.
Participants in the control arm will access a link to a
“Sexual Health after Cancer” web page of the American
Cancer Society (ACS). They will receive 3 email re-
minders. The ACS website link will be available each
time these participants access the True NTH website,
for example when they fill out their 3 month and
6 month surveys. They can also return to the True NTH
website at will throughout the time of the study. As
participants will enter the study prior to treatment, their
study participation will continue for approximately
7 months.
Measures
Measurement timeline that includes both the primary
measure and secondary measures is outlined in Table 2.
Description of the measures is included in this section.
Patient Reported Outcome Measure Information
System (PROMIS) Global Satisfaction with Sex Life
[49] measures patients’ and partners’ overall satisfaction
with their sex life. Participants respond to seven items
on a 5-point scale. A higher score reflects greater satis-
faction (Cronbach alpha = 0.92).
PROMIS Interest in Sex Life [49] measures patients’
and partners’ interest in sex. Participants will respond to
four items on a 5- point Likert scale. A higher score will
indicate a higher level of interest (Cronbach
alpha = 0.87).
PROMIS Sexual Activity [49] is a 13-item measure
that evaluates the frequency and type of sexual activity.
It is a descriptive measure.
PROMIS Use of Aids [49] is a 7-item measure that
assesses the use of hormones, personal lubrications,
medications, or devices intended to allow for or im-
prove sexual function. These items are intended to be
“stand alone” items and do not comprise a unidimen-
sional scale.
Table 2 Study measures and data collection timeline
Variable Measure Assessment
Baseline 3 Months 6 Months
Patient Partner Patient Partner Patient Partner
PRE-EXISTING AND CLINICAL CHARACTERISTICS
Demographics Demographic survey X X X X
Comorbidities Katz Comorbidity Questionnaire
Charlson Comorbidities Index
X X X X
Clinical data Medical Chart Review X X X
Patient prostate cancer
related symptoms
Expanded Prostate Cancer Index Composite (EPIC) X X X
Patient expectation of
sexual function
Expanded Prostate Cancer Index Composite-Exp (EPIC-Exp) X
Partner sexual function
Female Female Sexual Function Index (FSFI) X X X
Male The International Index of Erectile Function (IIEF) X X X
Expectations Expectation of Success of Treatment X X
PRIMARY OUTCOME
Global Satisfaction with Sex
Life
Patient Reported Outcome Measure Information System
(PROMIS) Global Sexual Satisfaction
X X X X
SECONDARY OUTCOMES
Interest in sex PROMIS Interest in Sex Life X X X X X X
Sexual activity PROMIS Sexual Activity X X X X X X
Resources
Use of Aids PROMIS Use of Aids X X X X X X
Knowledge Knowledge Building Assessment X X X X
Dyadic Coping Dyadic Coping Inventory (DCI) X X X X
Grief Prolonged Grief about the Loss of Sexual Function X X X X
Quality of Life Quality of Life EQ-5D X X X X X X
Satisfaction with Intervention Satisfaction with Intervention X X
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Knowledge Building Assessment is an 18-item meas-
ure that was adapted from a previous study. Ten items
assess knowledge about the effect of prostatectomy on
erections, understanding of penile rehabilitation, erectile
aids, expectations for erection recovery, flexible couple
sexuality, and barriers to sexual recovery. The items are
categorical variables and will be dichotomized. A sum-
mary score will be calculated.
Expanded Prostate Cancer Index Composite-26
(EPIC) [50] is a 26-item prostate cancer health-related
quality of life (HRQOL) instrument that assesses urinary,
bowel, sexual, and hormonal treatment-related symptoms
of prostate cancer. Participants respond to a Likert scale.
A higher score reflects higher function (Cronbach
alpha = 0.93). Sexual function cut-off scores of the EPIC
are: 0–33 (severe ED), 34–45 (moderate ED), 46–60 (mild/
moderate ED), 61–75 (mild ED), and above 75 (no ED).
EPIC-Exp [50] is a measure parallel to the EPIC, but
focused on expectations of functional recovery 1 year
after treatment.
Female Sexual Function Index (FSFI) [51] is a 19-
item questionnaire measure of sexual functioning in
women. It assesses six domains of sexual functioning:
sexual desire, arousal, lubrication, orgasm, satisfaction
and pain. A total score is a sum of the domain scores.
Participants respond to a Likert scale.
Dyadic Coping Inventory (DCI) [52] is a 16-item
questionnaire that assesses stress communication and
dyadic coping as perceived by (1) each partner about
their own coping (what I do when I am stressed and
what I do when my partner is stressed), (2) each part-
ner’s perception of the other’s coping (what my partner
does when he or she is stressed, and what my partner
does when I am stressed), and (3) each partner’s view of
how they cope as a couple (what we do when we are
stressed as a couple). Participants respond on a Likert
scale. A higher score reflects higher dyadic coping
(Cronbach alpha for subscales = 0.71–0.92).
Prolonged Grief about the Loss of Sexual Function
[53] is a 22-item scale that was adapted for sexual function
loss from the Prigerson’s validated measure of prolonged
grief in bereavement. Participants respond to a Likert scale.
The International Index of Erectile Function (IIEF)
[54] is a 15-item scale with subscales that measure erect-
ile function, orgasmic function, sexual desire, intercourse
satisfaction and overall satisfaction. Participants respond
on a Likert scale. A higher score reflects higher sexual
function. (Cronbach alpha for subscales and overall IIEF
is 0.91, 0.92, 0.92, 0.77, 0.73, 0.74, respectively). As
the IIEF was validated for heterosexual sex with vagi-
nal intercourse as the expected activity, several add-
itional items will be added for gay participants, but
not included in scoring to inform about gay sexual
experience.
Expectations of Success of Treatment [55] is a 10-
item measure, adapted from a mental health measure for
confidence regarding treatment for sexual dysfunction. It
measures confidence in the treatment and in the out-
come of the treatment. Participants respond on a Likert
scale. A higher score reflects greater confidence in the
success of treatment.
Quality of Life EQ-5D [56] is a standardized QOL in-
strument for use as a measure of health outcomes. It es-
sentially consists of 2 pages – the EQ-5D descriptive
system, and the EQ visual analogue scale (EQ VAS). The
EQ-5D-3 L descriptive system comprises the following 5
dimensions: mobility, self-care, usual actives, pain/dis-
comfort and anxiety/depression. Each dimension has 3
levels: no problems, some problems, extreme problems.
Demographic/Lifestyle Data Demographic data such
as age, partnership status, race/ethnicity, household in-
come, education, weight, height and cigarette smoking
status will be sought.
Comorbidities [57], such as heart disease, arthritis,
diabetes and others, will be collected on a self- reported
basis from both the patient and partner.
Satisfaction with Intervention is a 10-item survey
that was developed for this study by the study team and
has face validity. Participants respond to a Likert scale.
Individual items are summed into a total score. A higher
score means higher satisfaction.
Clinical data will be abstracted from patients’ health
records, including PSA and clinical stage of prostate
cancer at diagnosis, Gleason score, comorbidities as
rated per the Charlson Comorbidities Index [58], etc.
For surgical patients, pathological stage, margin status
(positive/negative), pathologic Gleason score and 3-
month post-surgery PSA at 3 will be collected.
Data analysis
Endpoints
The primary endpoint for this study will be the PROMIS
Sexual Satisfaction measure at the 6-month follow-up, a
multi-item validated assessment of satisfaction with sex life
that was designed to have a mean of 50 and a standard devi-
ation of 10 in the general population. Secondary endpoints
will consist of the other functional and QOL measurements,
comorbidities, and satisfaction assessments (Table 2).
Analysis
The primary endpoint of PROMIS Satisfaction with Sex
Life at 6 months is expected to be a continuous meas-
urement that is normally distributed. If not, we will
transform the data for this outcome to approximate nor-
mality. Since the primary outcome is measured on both
patients and partners and randomization was done at
the level of each dyad, we will assess the impact of the
intervention using the Actor-Partner Interaction Model
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(APIM) [59]. The APIM is a mixed-effects linear regres-
sion model that allows us to simultaneously estimate the
association of partner characteristics with partner and
patient outcomes, as well as simultaneously estimate the
association of patient characteristics with both out-
comes. The APIM incorporates random effects to ac-
count for the correlation between patient and partner
outcomes from the same dyad. Our base model will con-
tain (1) an indicator of intervention versus control, (2)
baseline PROMIS Satisfaction with Sex Life, (3) a indica-
tor of partner versus patient, (4) interaction terms of (3)
with (1) and (2), (5) a random partner effect to account
for variation among partners, (6) a random patient effect
to account for variation among patients, and (7) a third
random effect to account for the correlation (non-inde-
pendence) between outcomes measured from the same
dyad. From this base model, we can assess not only the
relative impact of the intervention among dyads, but
also the differential impact of the intervention on part-
ners and partners.
We can then expand our base model to include other
partner characteristics and/or patient characteristics to
assess whether or not these characteristics moderate or
mediate the effect of the intervention for the patient and
the partner. For example, we could include baseline sat-
isfaction with sex life of the partner and the patient and
see if either or both factors moderate or mediate the ef-
fect of the intervention on 6-month satisfaction with sex
life. We note that because dyads were randomized to the
intervention, we expect dyad level characteristics to have
little effect in our model because those factors should be
nearly balanced among the two treatment arms. Thus,
adjustment for them is unnecessary, except to gain stat-
istical power. The random effects will allow us to esti-
mate the remaining variability of outcomes among
partners, among patients, and the correlation of out-
comes within each dyad, that is not explained by our
APIM.
All secondary endpoints will be analyzed with an
APIM exactly as described for the primary endpoint. It
is possible that some secondary endpoints, even after
transformation, will have slightly skewed distributions.
However, random effect models are fairly robust to slight
deviations from normality.
Along with outcome data analyses, we will conduct an
analysis of the logistics of participant activity. This will
include participant engagement with the modules of the
intervention on the web, the need for reminders, time
spent on each module and number of times each mod-
ule was accessed.
Power calculations
Basing power calculation on the average adjusted PRO-
MIS Satisfaction with Sex Life score of 50 (standard
deviation = 10) provided in the PROMIS scoring and an-
ticipating Sexual Satisfaction scores for the intervention
group vs. control group to be 50 vs. 45 based on expert
opinion, a sample size of 128 patients and 128 spouse/
partners will provide 80% power at the 5% significance
level to detect this difference using a two-tailed t-test.
Adding 10%, or 14 dyads (including an extra one to get
to an even number to allow the same sample size in each
arm), to our total to account for the anticipated dyads
that will be lost to follow-up prior to study completion,
we will recruit 140 dyads (280 individuals) for this study
(expected to be 70 couples on each study arm).
Ethics
The study will be coordinated by the University of Mich-
igan, the protocol has been approved by the University
of Michigan Institutional Review Board (IRB) and by the
IRBs of all the other participating sites. The process of
the study and protocol modifications, if needed, will be
discussed in weekly meetings with all the sites and
amendments filed to each institution’s IRB. Data will be
collected by the University of Michigan Center for
Healthcare Communications Research (CHCR) and
stored securely on virtualized servers with a robust back
up system. All participants must sign informed consent
before enrolling in the study.
Discussion
Building on the acceptability of a previous web-based
intervention for couples after prostate cancer treatment,
which was shown to be as effective as a face-to-face
intervention [20], our intervention represents several in-
novations. It is based on an evidence-based theoretical
model that incorporates both a biopsychosocial ap-
proach to sexuality and the grief process, as a path to re-
covery. Unlike any previous sexual health intervention, it
is interactive and has a personalized approach achieved
through tailoring to treatment, partnership and sexual
orientation. When fully implemented, it will provide
support for men with prostate cancer and their partners
along the trajectory of the illness, including during dis-
ease progression and in the metastatic stage. This ap-
proach recognizes both the hard work that men and
couples undertake when they desire to maintain their
sexual viability after prostate cancer treatment, and the
fact that men and partners benefit from staying close
during all phases of illness. [60] Patients’ and partners’
quest to maintain sexual intimacy will be reinforced by
modules that provide coaching for discussions of sexual
concerns between the patient, partner and healthcare
provider and alert them to barriers to sexual recovery
with relevant strategies.
The evaluation of the intervention is also innovative. In
particular, we are investigating satisfaction with sex life,
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which may be applicable to a broad array of men, including
older men and their partners who may be able to attain/
maintain satisfaction with their sex life despite compro-
mised sexual function [61]. Furthermore, the study includes
many variables that are critical and relevant to a successful
sexual recovery, such as sexual function, grief about the loss
of sexual function, dyadic coping, knowledge acquisition,
some of which have been primary outcomes in previous
studies. Finally, our analytic approach allows us to evaluate
the couple which experiences prostate cancer as a unit with
reciprocal influence on each other’s outcomes. Our goal is
to provide an accessible, comprehensive and individually
relevant supportive structure for recovery from this well-
recognized long-term treatment effect [62], and to contrib-
ute positively to patients’ and partners’ quality of life in sur-
vivorship. When the study is completed, we plan to publish
the findings. Subsequently, the intervention will be modi-
fied, as needed, based on study findings and offered in full
on the Movember Foundation-True NTH website to all
prostate cancer survivors and their partners.
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